Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy-Reference-Cited by-同舟云学术

Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy

Published:2015-04 Issue:2 Volume:30 Page:149-153
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Ikeda Midori,Tsuji Daiki,Yamamoto Keisuke,Kim Yong-Il,Daimon Takashi,Iwabe Yutaro,Hatori Masahiro,Makuta Ryo,Hayashi Hideki,Inoue Kazuyuki,Nakamichi Hidenori,Shiokawa Mitsuru,Itoh Kunihiko

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference26 articles.

1. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer;Hughes;Clin Infect Dis,2002

2. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006

3. Role of anthracyclines in the treatment of early breast cancer;Gianni;J Clin Oncol,2009

4. Long-term toxic effects of adjuvant chemotherapy in breast cancer;Azim;Ann Oncol,2011

5. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review;Lal;Curr Drug Metab,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy;Cancers;2022-11-04

2. Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer;Supportive Care in Cancer;2022-05-24

3. Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy;Journal of Personalized Medicine;2022-04-11

4. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity;Pharmacogenomics;2021-01

5. Impact of variants in ATP-binding cassette transporters on breast cancer treatment;Pharmacogenomics;2020-12